A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

1. Provision to sign and date the consent form 2. Able to comply with all study procedures and be available for the duration of the study in the investigator's judgment 3. Age ≥18 4. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 5. Histologically or cytologically confirmed advanced or metastatic colorectal adenocarcinoma 6. Prior treatment with fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab (unless contraindicated) and cetuximab/panitumumab (for RAS-wild type disease) for the treatment of advanced or metastatic colorectal cancer and had demonstrated progressive di…